George Fritsma

MS, MLS, Lab Scientist, Educator, Author

George Fritsma is a medical laboratory scientist, educator, and author. George contributed five chapters to Keohane EM, Butina MM, Mirza KM, Walenga JM: Rodak’s Hematology; Clinical Principles and Applications, Seventh Edition, 2025, Elsevier; and is the co-author of Bennett A, Fritsma GA, Ernst DJ: Quick Guide to Blood Collection Edition 2, 2016, Marques MB, Fritsma GA: Quick Guide to Coagulation Testing Edition 3, 2015, and Reddy V, Marques MB, Fritsma GA: Quick Guide to Hematology Testing Edition 2, 2013, along with three additional titles, all published by AACC Press. He is a consultant in the Laboratory Medicine Department of Pathology at the University of Alabama at Birmingham. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

October 2026 QQ: Which is NOT an APL?

Our October 2026 Quick Question is a quiz that asks, “Which is NOT an antiphospholipid antibody?” The choices are… Anti beta-2 glycoprotein 1 Alpha-2 antiplasmin Lupus anticoagulant Antiprothrombin Anticardiolipin Antiphospholipid antibodies are acquired autoantibodies that bind phospholipid-bound proteins. Please go to the question on the right of your screen, make your selection, and add your […]

Comments (0)

Blog

Laboratory Diagnostics for Thrombosis and Hemostasis Testing

Here is a detailed introduction to the fifth “Seminars in Hemostasis and Thrombosis” issue devoted to laboratory testing: Smock KJ, Moffat KA. Laboratory diagnostics for thrombosis and hemostasis testing-Part V. Semin Thromb Hemost. 2026;52(8):887-888. doi: 10.1055/a-2912-7667. PMID: 42913665. The 14 citations are available as open-access articles.

Comments (0)

Events

A Meta-Analysis: Microplastics, Nanoplastics, and Thrombogenesis

Thanks to Dr. Emmanuel Favaloro for featuring this provocative open-access meta-analysis connecting microplastics and hemostasis. Balwan R, Hew YY, Gurumurthy G, et al. Microplastics, nanoplastics, and thrombogenesis. Res Pract Thromb Haemost. 2026;10(7):106931. doi: 10.1016/j.rpth.2026.106931. PMID: 42894845; PMCID: PMC13677222. Abstract Micro- and nanoplastics (MNPs) are produced through mechanical, chemical, and ultraviolet-mediated degradation of plastics and may […]

Comments (0)

Thrombophilia

Summary--Current Hemophilia Therapy: FVIII Bypassing and Rebalancing

Click for an illustrated outline in Hemophilia Today, “The Rebalanced Patient: New Therapies and New Thrombotic Risks in Hemophilia.” Introduction For decades, the central therapeutic principle in hemophilia was straightforward: replace what was missing. In hemophilia A, this meant replacing FVIII; in hemophilia B, FIX. Prophylactic factor replacement transformed hemophilia from a condition dominated by recurrent […]

Comments (0)

Bleeding Disorders

Can We Confirm a DOAC Overdose?

Here’s a provocative question from Sacha N. Uljon, MD, PhD, Medical Director, Massachusetts General Brigham Special Coagulation Integrated Laboratory Service: Hello, this post is about lab findings in apixaban overdose. We have now seen two suicide attempts involving apixaban. There was no clot at all on the PT/PTT (Werfen/Hemosil), so the anti-Xa level can’t be […]

Comments (0)

Anticoagulant Therapy

A World Thrombosis Day Post: Blood Clots Can Affect Anyone

Dr. Ali Sadeghi-Khomami: On World Thrombosis Day (13 October), a simple reminder: blood clots can affect anyone, and where a clot forms can have very different consequences. Let’s continue raising awareness about thrombosis, its risk factors, and the importance of early recognition. Know your risk. Recognize the signs. Take action.

Comments (0)

Thrombophilia

Reduced-dose DOACs in Cancer-associated Thrombosis

Click for this open-access retrospective cohort study reporting the safety and efficacy outcomes for reduced-dose DOACS: Santini P, Santagata D, Mosoni C, et al. Full- versus reduced-dose direct oral anticoagulants for extended treatment of cancer-associated thrombosis: a multicenter retrospective cohort study. Semin Thromb Hemost. 2026. doi: 10.1055/a-2904-5824. PMID: 42379243. Abstract Extended anticoagulation is recommended in […]

Comments (0)

Anticoagulant Therapy

What is Fibrinogen Longmont?

Click here for an open-access case report of a variant fibrinogen: Ma C, Li X, Yin D, et al. Rapid laboratory identification of fibrinogen Longmont: a case report and literature review. Front Med (Lausanne). 2026;13:1781076. doi: 10.3389/fmed.2026.1781076. PMID: 42440479; PMCID: PMC13333428. Abstract This study reports a case of a patient with unstable angina with abnormally […]

Comments (0)

Bleeding Disorders

Heparin Effect on Chemiluminescence HIT Testing

Check with your local library for this HIT testing report: Vong R, Pasalic L, Donikian D, Brighton T, Favaloro EJ. Effect of heparin on immunological heparin-induced thrombocytopenia-IgG chemiluminescence testing. Blood Coagul Fibrinolysis. 20261;37(7):329-335. doi: 10.1097/MBC.0000000000001456. PMID: 42615582. Heparin-induced thrombocytopenia (HIT) requires clinical evaluation and laboratory testing using immunological assays with confirmation by functional assays such […]

Comments (0)

Anticoagulant Therapy

Illustrated Review: Acquired Hemophilia A

Here is a richly illustrated review of acquired hemophilia A: Guillet B, d’Oiron R, Lacroix-Desmazes S, et al. Acquired hemophilia A: an illustrated review based on the French National Guidelines. Res Pract Thromb Haemost. 2026;10(5):106820. doi: 10.1016/j.rpth.2026.106820. PMID: 42657325; PMCID: PMC13508639. Abstract Acquired hemophilia A is a rare but potentially life-threatening autoimmune bleeding disorder caused […]

Comments (0)

Bleeding Disorders

Questions or Comments?

Email George